-
Mashup Score: 1As digital health unicorns are pressured to do more with less, Transcarent gets a fresh $126M - 10 hour(s) ago
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Transcarent’s $126 million Series D round, which in May bumped its valuation to $2.2 billion, stands apart from most growth-stage, high-valuation startups that haven’t raised capital in the past few years. While
Source: endpts.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 2Exclusive: Feng Zhang CRISPR startup gathers patents, locking up rights to family of editing tech - 19 hour(s) ago
In the bid to lock up patent rights to a growing suite of gene-editing technologies, Arbor Biotechnologies has acquired a small startup founded by MIT scientist and CRISPR pioneer Feng Zhang, the company exclusively told Endpoints News. Zhang’s startup, Serendipity Bioscience, has never disclosed how much funding it raised, and
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign: getting viruses to work for us, instead of against us. Now, after three years in stealth, Prologue Medicines launched Tuesday morning and unveiled its plan
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Exclusive: New York biotech debuts with $16M to find new ways to make solid cancer cell therapies - 1 day(s) ago
A new biotech is coming out of stealth with $16 million to develop cell therapies for solid cancers — an area where scientists have had limited success. OverT Bio (pronounced
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3
Senate HELP Committee ranking member Bill Cassidy (R-LA) is calling on the Biden administration to do a better job of communicating its findings on the recent outbreak of avian flu among cattle that has infected at least one human. In a three-page letter sent to President Biden on Friday, Cassidy
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 8
Novartis will pay $1 billion upfront to acquire radiopharmaceutical startup Mariana Oncology, just eight months after the preclinical biotech company disclosed a $175 million Series B. The move, which could include another $750 million in milestones, further solidifies the Swiss drug giant’s embrace of the red-hot field of radiopharmaceuticals. Novartis
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
GSK’s vaccines portfolio is front and center as it kicks off 2024. The UK pharma made £7.36 billion ($9.18 billion) in the first three months of the year, with its vaccine products contributing £2.27 billion ($2.83 billion). Its shingles vaccine Shingrix drew £945 million ($1.2 billion) and its RSV product
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 4
Real Chemistry plans to harness the “Wild West” of GLP-1 social media and reams of competitive data in the drug category with a new platform called IRIS. An all-in-one dashboard sits at the center of the service with real-time data that include clinical trial tracking, script and claims information, consumer
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 12
Novartis is looking to build on its radiopharma research machinery. The maker of Lutathera and Pluvicto has expanded its long-standing peptide discovery deal with PeptiDream to bolster their work on peptides for conjugation with radionuclide compounds. The Japanese biotech, which has a long list of drug development partners, will get
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Merck bolstered its pneumococcal vaccine data on Monday, suggesting its experimental 21-valent shot V116 offers broader protection for older adults than Pfizer’s market-leading 20-valent Prevnar 20. An approval in the coming weeks would stoke Merck’s yearslong rivalry with Pfizer, whose Prevnar 20 was first approved in 2021, a mere month before
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
As digital health unicorns are pressured to do more with less, Transcarent gets a fresh $126M https://t.co/khvw7Ydzch https://t.co/fO7Td59fyx